Search results for Ludus AI

Ludus AI is an AI toolkit for Unreal Engine 5 developers that helps offers several modules including LudusDocs, an AI expert providing instant answers to UE5 questions; LudusBlueprint, an AI copilot assisting with Blueprint graphs; and LudusCode, a C++ autocomplete tool. Key capabilities include faster onboarding, reduced prototyping time, Blueprint graph clarity, and access to UE5 knowledge. Speeding up and upgrading gamedev existance. Ludus AI is a technology company introducing a next-generation solution for the 3D game and visualization industry. The startup, founded by Piotr Penar, former CEO of DreamStorm Studios, aims to facilitate the creation of high-quality content in Unreal Engine by using artificial intelligence. Unreal Engine, although recognized as the best tool for creating 3D experiences, presents significant challenges for creators. Complicated documentation and complex processes often lead to extended production times and increased costs. Ludus AI was created in response to these problems, resulting from the founder's direct experience in managing a 60-person team of developers during a 9-year journey through the gaming industry and working on projects for Microsoft, Google and UPS. The company has created a comprehensive set of tools that significantly speed up work in Unreal Engine, offering users not only the basic capabilities offered by AI technology, such as project and blueprint analysis, but also the innovative ability to automatically create objects in virtual space based solely on a description. Ludus AI solutions are used in many industries. Game studios can significantly accelerate the development process of projects, architectural firms gain the ability to quickly create interactive visualizations, and the training and simulation sector can more effectively create advanced training environments. The technology also works in the automotive industry in the design of user interfaces and in film production in the creation of virtual film sets. The company, which recently released the first version of its solution, is already attracting the attention of the industry, has over 5,000 users and plans further expansion into international markets. In the coming months, Ludus AI will focus on scaling as interest grows, stability of its product, adding more features to its assortment and developing its most frequently used and most effective tool, which is the creation of 3D objects by description.

Automate your productivity with Ai Co-workers. Ai SDR - Lucus, Ai HR - Ella, Ai EA

BenevolentAI is a leading clinical-stage company that integrates artificial intelligence (AI) with scientific expertise to revolutionize drug discovery and development. By leveraging its proprietary Benevolent Platform™, the company uncovers novel biological insights, predicts new drug targets, and develops first-in-class or best-in-class therapeutics for complex diseases. This innovative approach aims to enhance the efficiency and success rates of bringing new medicines to patients. Key Features and Functionality: - AI-Driven Target Identification: Utilizes advanced AI tools to analyze vast datasets, identifying novel drug targets with higher precision. - Integrated Scientific Expertise: Combines AI capabilities with in-house scientific knowledge and wet-lab facilities to validate findings and accelerate drug development. - Collaborative Partnerships: Engages in strategic collaborations with pharmaceutical companies like AstraZeneca and Merck to co-develop innovative treatments. - Diverse Therapeutic Focus: Develops a broad pipeline addressing various complex diseases, including idiopathic pulmonary fibrosis, chronic kidney disease, systemic lupus erythematosus, and heart failure. Primary Value and Problem Solved: BenevolentAI addresses the challenges of traditional drug discovery, which often involve high costs, lengthy timelines, and low success rates. By integrating AI with scientific research, the company streamlines the identification of viable drug targets and accelerates the development process. This approach not only reduces the time and resources required to bring new therapies to market but also increases the likelihood of clinical success, ultimately delivering innovative medicines to patients more efficiently.